Mosaic variegated aneuploidy syndrome

Lore & Background

The earliest known description of MVA is often attributed to Warburton and colleagues in 1991, who also coined the name. The disorder is caused by defects in genes responsible for the spindle checkpoint, which is necessary for correct chromosome splitting during mitosis. Mutations in BUB1B, BUB3, CEP57, and TRIP13 disrupt this process, leading to aneuploidy in some cells.

Reader's Guide

Mosaic variegated aneuploidy syndrome is significant as a model for understanding the spindle checkpoint and its role in chromosomal segregation. The disorder highlights the importance of genes such as BUB1, BUB1B, BUB3, CEP57, and TRIP13 in maintaining genomic stability. Its wide range of symptoms—from cataracts and Dandy-Walker malformation to tumors like acute lymphoblastic leukemia—underscores the systemic impact of mosaic aneuploidy. Diagnosis relies on phenotype suspicion confirmed by karyotyping and genetic testing. Prognosis varies depending on the types of malformation present. With a prevalence of 1 in 1,000,000, MVA is extremely rare, but its study has contributed to broader knowledge of cell cycle regulation and aneuploidy-related diseases.

Did You Know?

• MVA is caused by mutations in BUB1B, BUB3, CEP57, or TRIP13.
• The earliest known description of MVA is often attributed to Warburton and colleagues in 1991.
• Individuals with MVA may present with tumors such as acute lymphoblastic leukemia, nephroblastoma, or rhabdomyosarcoma.
• The prevalence of MVA is 1/1,000,000.